REMIFENTANIL HYDROCHLORIDE

Electrolyte / Mineral

Brand names: Ultiva

Intravenous

Mechanism of Action

12.1 Mechanism of Action ULTIVA is a µ-opioid agonist with rapid onset and peak effect, and short duration of action. The µ-opioid activity of ULTIVA is antagonized by opioid antagonists such as naloxone. Unlike other opioids, ULTIVA is rapidly metabolized by hydrolysis of the propanoic acid-methyl ester linkage by nonspecific blood and tissue esterases. ULTIVA is not a substrate for plasma cholinesterase (pseudocholinesterase) and, therefore, patients with atypical cholinesterase are expected to have a normal duration of action.

Indications

See full prescribing information

Contraindications

• anaphylaxis). ( 4 )

FDA Warnings

5 WARNINGS AND PRECAUTIONS • Life-Threatening Respiratory Depression : Monitor closely, particularly during initiation and titration
2 ) • Risks from Use as Postoperative Analgesia with Concomitant Benzodiazepines or other CNS Depressants : Hypotension, profound sedation, respiratory depression, coma, and death may result from the concomitant use of ULTIVA with benzodiazepines or other CNS depressants ( 5
11 ) • Risks of Use in Spontaneously Breathing Patients with Increased Intracranial Pressure, Brain Tumors, Head Injury, or Impaired Consciousness : Monitor for sedation and respiratory depression
12 ) • Risks of Use in Patients with Biliary Tract Disease : Monitor patients with biliary tract disease, including acute pancreatitis, for worsening symptoms

Known Side Effects

4 documented side effects by frequency

Low Blood Pressure

>10%

Rapid Heart Rate

1-10%

Rash

0.1-1%

Drug Not Working

0.1-1%

Community Discussions

No community discussions found for REMIFENTANIL HYDROCHLORIDE yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Intravenous